145 related articles for article (PubMed ID: 34389273)
21. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
Suzuki K; Min CK; Kim K; Lee JJ; Shibayama H; Ko PS; Huang SY; Li SS; Ding B; Khurana M; Iida S
Int J Hematol; 2021 Dec; 114(6):653-663. PubMed ID: 34410635
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa MC; Zhang L; Hitz F; Novak U; Hess D; Terrot T; Pascale M; Mazzucchelli L; Bertoni F; Cavalli F; Zucca E; Stathis A
Leuk Lymphoma; 2022 Jan; 63(1):117-123. PubMed ID: 34407735
[TBL] [Abstract][Full Text] [Related]
23. Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis.
Kong Y; Hong L; Xu X; Xu J
Medicine (Baltimore); 2021 Aug; 100(31):e26862. PubMed ID: 34397863
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis.
Zhang H; You J; Liu W; Chen D; Zhang S; Wang X
Medicine (Baltimore); 2021 Jul; 100(30):e26714. PubMed ID: 34397704
[TBL] [Abstract][Full Text] [Related]
25. Investigating the inequalities in route to diagnosis amongst patients with diffuse large B-cell or follicular lymphoma in England.
Smith MJ; Fernandez MAL; Belot A; Quartagno M; Bonaventure A; Majano SB; Rachet B; Njagi EN
Br J Cancer; 2021 Oct; 125(9):1299-1307. PubMed ID: 34389805
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic follicular lymphoma: a report of two cases and literature review.
Okamoto T; Sasaki T; Nishimura N; Takamatsu M; Mori C; Mie T; Furukawa T; Yamada Y; Takeda T; Kasuga A; Matsuyama M; Ozaka M; Maruyama D; Sasahira N
Clin J Gastroenterol; 2021 Dec; 14(6):1756-1765. PubMed ID: 34453279
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China.
Zha J; Fan L; Yi S; Yu H; Zheng Z; Xu W; Deng M; Lin Z; Li Z; Ping L; He X; Chen F; Xie Y; Chen B; Zhang H; Wang L; Ding K; Li W; Yang H; Zhao W; Qiu L; Li Z; Song Y; Xu B
J Hematol Oncol; 2021 Aug; 14(1):131. PubMed ID: 34425858
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.
Jiang B; Qi J; Song Y; Li Z; Tu M; Ping L; Liu Z; Bao H; Xu Z; Qiu L
J Hematol Oncol; 2021 Aug; 14(1):130. PubMed ID: 34425850
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
Nishizawa Y; Haraguchi N; Kim H; Ide Y; Nakata K; Okamura S; Kudo T; Satoh T; Uemura M; Matsuda C; Mizushima T; Murata K; Doki Y; Eguchi H
BMC Cancer; 2021 Aug; 21(1):947. PubMed ID: 34425776
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Forsberg PA; Rossi AC; Boyer A; Pearse RN; Pekle KA; Jayabalan D; Lakritz S; Flicker K; Ribadeneyra D; Liotta B; Ely S; Boussi L; Allan JN; Coleman M; Niesvizky R; Mark TM
Am J Hematol; 2021 Dec; 96(12):1554-1562. PubMed ID: 34424561
[TBL] [Abstract][Full Text] [Related]
31. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
32. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.
Chen DG; Chen G; Wang C; Ke LF; Wu H; He HM; Yang Y; Chen YP
Infect Agent Cancer; 2021 Aug; 16(1):57. PubMed ID: 34404436
[TBL] [Abstract][Full Text] [Related]
34. Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants.
Casal MA; Ivy SP; Beumer JH; Nolin TD
Lancet Oncol; 2021 Sep; 22(9):1333-1340. PubMed ID: 34399096
[TBL] [Abstract][Full Text] [Related]
35. Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
Eichenauer DA; Bühnen I; Kreissl S; Goergen H; Fuchs M; von Tresckow B; Rosenwald A; Klapper W; Hansmann ML; Möller P; Bernd HW; Feller AC; Engert A; Borchmann P; Hartmann S
Br J Haematol; 2022 Jan; 196(1):99-104. PubMed ID: 34396513
[TBL] [Abstract][Full Text] [Related]
36. Management of IgA Vasculitis with Nephritis.
Delbet JD; Parmentier C; Herbez Rea C; Mouche A; Ulinski T
Paediatr Drugs; 2021 Sep; 23(5):425-435. PubMed ID: 34396492
[TBL] [Abstract][Full Text] [Related]
37. Cryoglobulinemia unmasked by nivolumab in a patient with hepatitis C-induced hepatocellular carcinoma: A case report and literature review.
Ramahi A; Chan KH; Lim SL; Shaaban HS
Int J Crit Illn Inj Sci; 2021; 11(2):95-97. PubMed ID: 34395211
[TBL] [Abstract][Full Text] [Related]
38. Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients.
Čerina D; Matković V; Katić K; Belac Lovasić I; Šeparović R; Canjko I; Jakšić B; Petrić-Miše B; Bajić Ž; Boban M; Vrdoljak E
J Oncol; 2021; 2021():2815623. PubMed ID: 34394349
[TBL] [Abstract][Full Text] [Related]
39. Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region.
Bose B; Badve SV; Johnson DW; Hawley C; Jha V; Reidlinger D; Peh CA
Nephrology (Carlton); 2022 Jan; 27(1):35-43. PubMed ID: 34392579
[TBL] [Abstract][Full Text] [Related]
40. Oral/oesophageal candidiasis is a risk factor for severe infection after kidney transplantation.
Abe T; Futamura K; Goto N; Ohara K; Ogasa T; Tomosugi T; Okada M; Hiramitsu T; Narumi S; Watarai Y
Nephrology (Carlton); 2022 Jan; 27(1):97-103. PubMed ID: 34390080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
